API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

12 clusters · 172 sources · 54 days · First seen · Last updated

Brazil plans semaglutide integration into SUS

Overview

The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to the National Commission for the Incorporation of Technologies in the SUS (Conitec) to establish clinical protocols. The initiative, which aligns with President Lula’s reelection campaign promises, aims to serve millions of patients, targeting obesity, a condition affecting approximately 25% of the population. The Ministry estimates an annual investment of R$ 1.5 billion, suggesting that bulk purchasing could lead to government discounts of up to 90%. To prevent ‘purely aesthetic purposes,’ the program will prioritize high-risk individuals, such as those awaiting bariatric surgery or those with obesity-related comorbidities like heart disease. A pilot study, Real-Bari, is currently monitoring 250 patients in Porto Alegre to establish safety guidelines. On October 27, 2026, Anvisa approved the registration of five new GLP-1 receptor agonist pens: Aribet, Lyrza, Wylovol, Embeltah, and Sevema. On November 4, 2026, Anvisa approved the oral tablet version of Wegovy, marking the first authorized oral GLP-1 receptor agonist in Brazil. Expanding on these regulatory developments, Anvisa approved two new injectable semaglutide medications, a generic version and a similar product named Loryvia, registered by Ávita Care Importação e Distribuição de Produtos Ltda. These products follow the recent patent expiration of Ozempic and aim to increase the national supply of GLP-1 receptor agonists, a priority for the Ministry of Health. Concurrently, Anvisa ordered the seizure of the unregistered weight-loss product Ultra Shape by Ciência da Natureza, along with various unauthorized supplements and cleaning products sold on e-commerce platforms. On November 9, 2026, Anvisa expanded its regulatory actions, noting that the total number of registered GLP-1 receptor agonist pens reached 22 in 2026.

Entities

Brazil · Ministry of Health · Anvisa · SUS · Luiz Inácio Lula da Silva

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [HEALTH] 27 sources
    Anvisa regulates weight-loss medications and seizes irregular supplements

    Anvisa approved two new semaglutide-based weight-loss medications while seizing various unregistered supplements and products sold on major e-commerce platforms in Brazil.

  2. [HEALTH] 54 sources
    Anvisa approves oral Wegovy for obesity treatment in Brazil

    Anvisa has approved the oral version of Wegovy (semaglutide) in Brazil, the first oral GLP-1 agonist for obesity treatment in the country.

  3. [HEALTH] 15 sources
    Anvisa approves five new GLP-1 medications for diabetes and obesity

    Anvisa has approved five new GLP-1 medications for diabetes and obesity in Brazil, bringing the 2026 total for this drug class to 20 approvals.

  4. [BUSINESS] 2 sources
    Protein and creatine sales surge in Brazilian retail market

    Brazilian retail sales of whey protein and creatine have surged, driven by fitness trends and the use of GLP-1 medications for weight management.

  5. [HEALTH] 7 sources
    Weight loss medication trends impact pharmacy logistics and clinical guidelines

    The growing use of weight loss medications is transforming pharmacy e-commerce logistics in Brazil and prompting European health experts to call for multidisciplinary medical supervision.

  6. [BUSINESS] 6 sources
    GLP-1 weight loss drug prescriptions surge 304.9% in Brazil

    Digital prescriptions for GLP-1 weight loss drugs in Brazil rose 304.9% in 2025, as Mounjaro gains market share and new similar products drive down retail prices.

  7. [HEALTH] 5 sources
    Brazil: Protein intake importance rises with GLP-1 weight-loss medication use

    As GLP-1 weight-loss medication use reaches 33% of Brazilian households, experts urge high protein intake, such as tilapia, to preserve muscle mass during reduced appetite.

  8. [POLITICS] 9 sources
    Brazil Ministry of Health announces plan for weight-loss drugs in SUS

    Brazil's Ministry of Health is seeking to incorporate semaglutide into the SUS, potentially saving 90% through bulk purchasing, amid debates over electoral advertising rules.

  9. [HEALTH] 3 sources
    Brazil to provide semaglutide weight loss drugs via SUS

    Brazil is integrating semaglutide weight loss medications into the SUS, prioritizing high-risk patients and those with comorbidities to ensure responsible use rather than purely aesthetic purposes.

  10. [HEALTH] 61 sources
    Brazil Ministry of Health requests GLP-1 weight-loss drugs for SUS

    Brazil's Ministry of Health has asked Conitec to include GLP-1 weight-loss medications, such as semaglutide, in the SUS public health system, citing rising obesity rates and lower drug costs.

  11. [POLITICS] 3 sources
    Lula promises free weight-loss medication via SUS amid tight election

    President Lula da Silva announced that Brazil's SUS will provide free weight-loss medications for obesity patients amid a close election race against Flávio Bolsonaro.

  12. [HEALTH] 50 sources
    Brazil to provide weight-loss medications through SUS

    Brazil's government announced plans to provide weight-loss medications like semaglutide for free via the SUS, targeting severe obesity and patients awaiting bariatric surgery under strict clinical protocols.

Sources

98fmapucarana.com.br · 98fmnatal.com.br · abcmais.com · acessa.com · acidadenoticia.com.br · acordacidade.com.br · acritica.com · agorarn.com.br · algomais.com · amazoniaonline.com.br · anoticiaregional.com.br · api.metro1.com.br · aquiacontece.com.br · araucarianoar.com.br · areavip.com.br · aredacao.com.br · atarde.com.br · atibaia.com.br · bahianoticias.com.br · bandab.com.br · blogdomagno.com.br · blogdopaulinho.com.br · bloomberglinea.com.br · boasnovasmg.com.br · bpmoney.com.br · br.paipee.com · brasil.estadao.com.br · brasil247.com · brasilemfolhas.com.br · bsbtimes.com.br · campos24horas.com.br · capitalnews.com.br · caririceara.com · cartacapital.com.br · catracalivre.com.br · cenariomt.com.br · cnnbrasil.com.br · comandonoticia.com.br · comunhao.com.br · conexaoto.com.br · consultorsalud.com · contilnetnoticias.com.br · destakjornal.com.br · dev.tnonline.com.br · dgabc.com.br · diaadianoticia.com.br · diabetesnsw.com.au · diariodecanoas.com.br

This summary has been updated 32 times: see revision history